These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 8877541

  • 1. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
    Rolston KV, Dholakia N, Ho DH, LeBlanc B, Dvorak T, Streeter H.
    J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
    [Abstract] [Full Text] [Related]

  • 2. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
    Lawrence T, Rotstein C, Beam TR, Gorzynski EA, Amsterdam D.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
    O'Hare MD, Felmingham D, Grüneberg RN.
    Drugs Exp Clin Res; 1988 Apr; 14(10):617-9. PubMed ID: 2977587
    [Abstract] [Full Text] [Related]

  • 5. In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.
    O'Hare MD, Ghosh G, Felmingham D, Grüneberg RN.
    J Antimicrob Chemother; 1990 Feb; 25(2):217-20. PubMed ID: 2139436
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 7. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2748-2756. PubMed ID: 29982565
    [Abstract] [Full Text] [Related]

  • 8. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb 01; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov 01; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ.
    Antimicrob Agents Chemother; 2003 Jul 01; 47(7):2334-8. PubMed ID: 12821492
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of teicoplanin against gram-positive cocci.
    Allouch P, Pina P, Chaplain C, Delarbre JM, Geffroy F, Grasmick CP, Marcolin M, Morel A, Pangon B, Rio Y, Sédaillan A.
    Pathol Biol (Paris); 2000 Oct 01; 48(8):792-5. PubMed ID: 11244609
    [Abstract] [Full Text] [Related]

  • 12. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.
    Maple PA, Hamilton-Miller JM, Brumfitt W.
    J Antimicrob Chemother; 1989 Apr 01; 23(4):517-25. PubMed ID: 2526111
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
    Ristow TA, Noskin GA, Warren JR, Peterson LR.
    Microb Drug Resist; 1995 Apr 01; 1(4):335-9. PubMed ID: 9158806
    [Abstract] [Full Text] [Related]

  • 14. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997 Apr 01; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
    Collins LA, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC.
    Antimicrob Agents Chemother; 1993 Jun 01; 37(6):1364-6. PubMed ID: 8328787
    [Abstract] [Full Text] [Related]

  • 16. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies.
    Boger DL.
    Med Res Rev; 2001 Sep 01; 21(5):356-81. PubMed ID: 11579438
    [Abstract] [Full Text] [Related]

  • 17. Novel pharmaceutical molecules against emerging resistant gram-positive cocci.
    Manfredi R, Sabbatani S.
    Braz J Infect Dis; 2010 Sep 01; 14(1):96-108. PubMed ID: 20428664
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
    Biavasco F, Manso E, Varaldo PE.
    Antimicrob Agents Chemother; 1991 Jan 01; 35(1):195-7. PubMed ID: 1826593
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of the semisynthetic glycopeptide amide MDL 63,246.
    Kenny MT, Brackman MA, Dulworth JK.
    Antimicrob Agents Chemother; 1995 Jul 01; 39(7):1589-90. PubMed ID: 7492109
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S, Tebbs SE, Elliott TS.
    J Antimicrob Chemother; 1998 Feb 01; 41(2):273-6. PubMed ID: 9533471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.